AFFITECH RESEARCH AS;PEREGRINE PHARMACEUTICALS, INC.
发明人:
申请号：
EP08846743.6
公开号：
EP2219672B1
申请日:
2008.11.07
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
